213 related articles for article (PubMed ID: 37278114)
1. Patient-derived preclinical models to develop immunotherapies.
Seoane J
Mol Oncol; 2023 Jul; 17(7):1169-1172. PubMed ID: 37278114
[TBL] [Abstract][Full Text] [Related]
2. In Vivo Modeling of Tumor Heterogeneity for Immuno-Oncology Studies: Failures, Improvements, and Hopes.
DiMarco AV; Maddalo D
Curr Protoc; 2022 Mar; 2(3):e377. PubMed ID: 35255200
[TBL] [Abstract][Full Text] [Related]
3. Microfluidic technologies for immunotherapy studies on solid tumours.
Paterson K; Zanivan S; Glasspool R; Coffelt SB; Zagnoni M
Lab Chip; 2021 Jun; 21(12):2306-2329. PubMed ID: 34085677
[TBL] [Abstract][Full Text] [Related]
4. Mouse Models for Cancer Immunotherapy Research.
Olson B; Li Y; Lin Y; Liu ET; Patnaik A
Cancer Discov; 2018 Nov; 8(11):1358-1365. PubMed ID: 30309862
[TBL] [Abstract][Full Text] [Related]
5. Rethinking the immunotherapy numbers game.
Bekker RA; Zahid MU; Binning JM; Spring BQ; Hwu P; Pilon-Thomas S; Enderling H
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793871
[TBL] [Abstract][Full Text] [Related]
6. Modeling the Tumor Microenvironment and Cancer Immunotherapy in Next-Generation Humanized Mice.
Chen A; Neuwirth I; Herndler-Brandstetter D
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296949
[TBL] [Abstract][Full Text] [Related]
7. The hubris and humility of cancer pharmacology in the post immuno-oncology era.
Lazo JS
Pharmacol Res Perspect; 2019 Dec; 7(6):e00527. PubMed ID: 31624635
[TBL] [Abstract][Full Text] [Related]
8. Challenges and next steps in the advancement of immunotherapy: summary of the 2018 and 2020 National Cancer Institute workshops on cell-based immunotherapy for solid tumors.
Fogli LK; Aurigemma R; Sommers CL; Singh A; Bourcier K; Ernstoff MS;
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34266886
[TBL] [Abstract][Full Text] [Related]
9. Immuno-oncology-101: overview of major concepts and translational perspectives.
Allard B; Aspeslagh S; Garaud S; Dupont FA; Solinas C; Kok M; Routy B; Sotiriou C; Stagg J; Buisseret L
Semin Cancer Biol; 2018 Oct; 52(Pt 2):1-11. PubMed ID: 29428479
[TBL] [Abstract][Full Text] [Related]
10. Humanized Mice for the Study of Immuno-Oncology.
De La Rochere P; Guil-Luna S; Decaudin D; Azar G; Sidhu SS; Piaggio E
Trends Immunol; 2018 Sep; 39(9):748-763. PubMed ID: 30077656
[TBL] [Abstract][Full Text] [Related]
11. 3D Tumor Models and Their Use for the Testing of Immunotherapies.
Boucherit N; Gorvel L; Olive D
Front Immunol; 2020; 11():603640. PubMed ID: 33362787
[TBL] [Abstract][Full Text] [Related]
12. Faithful preclinical mouse models for better translation to bedside in the field of immuno-oncology.
Saito R; Kobayashi T; Kashima S; Matsumoto K; Ogawa O
Int J Clin Oncol; 2020 May; 25(5):831-841. PubMed ID: 31407168
[TBL] [Abstract][Full Text] [Related]
13. Humanized mouse models for immuno-oncology research.
Chuprin J; Buettner H; Seedhom MO; Greiner DL; Keck JG; Ishikawa F; Shultz LD; Brehm MA
Nat Rev Clin Oncol; 2023 Mar; 20(3):192-206. PubMed ID: 36635480
[TBL] [Abstract][Full Text] [Related]
14. Leveraging Patient-Derived Models for Immunotherapy Research.
Politi K
Am Soc Clin Oncol Educ Book; 2020 May; 40():e344-e350. PubMed ID: 32511030
[TBL] [Abstract][Full Text] [Related]
15. Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer.
Annapragada A; Sikora A; Bollard C; Conejo-Garcia J; Cruz CR; Demehri S; Demetriou M; Demirdjian L; Fong L; Horowitz M; Hutson A; Kadash-Edmondson K; Kufe D; Lipkin S; Liu S; McCarthy C; Morgan M; Morris Z; Pan Y; Pasquini M; Schoenberger S; Van Allen E; Vilar E; Xing Y; Zha W; ; Odunsi A
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554617
[TBL] [Abstract][Full Text] [Related]
16. Cancer Immunoediting in the Era of Immuno-oncology.
Gubin MM; Vesely MD
Clin Cancer Res; 2022 Sep; 28(18):3917-3928. PubMed ID: 35594163
[TBL] [Abstract][Full Text] [Related]
17. Artificial Intelligence-based Radiomics in the Era of Immuno-oncology.
Kang CY; Duarte SE; Kim HS; Kim E; Park J; Lee AD; Kim Y; Kim L; Cho S; Oh Y; Gim G; Park I; Lee D; Abazeed M; Velichko YS; Chae YK
Oncologist; 2022 Jun; 27(6):e471-e483. PubMed ID: 35348765
[TBL] [Abstract][Full Text] [Related]
18. Advances and Challenges in Interventional Immuno-Oncology Locoregional Therapies.
Altun I; Demirlenk YM; Atar D; Cevik E; Gunduz S; Albadawi H; Oklu R
J Vasc Interv Radiol; 2024 Feb; 35(2):164-172. PubMed ID: 38272636
[TBL] [Abstract][Full Text] [Related]
19. Cancer Immunotherapy Getting Brainy: Visualizing the Distinctive CNS Metastatic Niche to Illuminate Therapeutic Resistance.
Owyong M; Hosseini-Nassab N; Efe G; Honkala A; van den Bijgaart RJE; Plaks V; Smith BR
Drug Resist Updat; 2017 Nov; 33-35():23-35. PubMed ID: 29145972
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy discovery on tumor organoid-on-a-chip platforms that recapitulate the tumor microenvironment.
Zhang J; Tavakoli H; Ma L; Li X; Han L; Li X
Adv Drug Deliv Rev; 2022 Aug; 187():114365. PubMed ID: 35667465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
